Halozyme Therapeutics HALO Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Halozyme Therapeutics (HALO) reported accretion (amortization) of discounts and premiums, investments of $30K in Q1 2026.
- How has Halozyme Therapeutics's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Halozyme Therapeutics's accretion (amortization) of discounts and premiums, investments decreased by 98.2% year-over-year, from $1.71M to $30K.
- What is the long-term trend for Halozyme Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's accretion (amortization) of discounts and premiums, investments has grown at a 9.9% compound annual growth rate (CAGR), from -$2.26M to $3.3M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustments to the carrying value of investment securities, such as the accretion of discounts or amortization of premiums on held-to-maturity or available-for-sale debt securities. It reconciles the interest income recognized with the actual cash received.